Calzada Limited (Calzada), formerly Metabolic Pharmaceuticals Limited, is a biotechnology company. It conducts its operations trough its subsidiaries, namely, Metabolic Pharmaceuticals Pty Ltd (Metabolic) and PolyNovo Biomaterials Pty Ltd. (PolyNovo). The company, through PolyNovo, has developed the NovoSorb technology, which carries out the development of medical devices for pharmaceutical and healthcare industry. It focuses on a wide range of therapeutic areas such as diverse wounds, burns, cardiovascular, orthopaedic, periodontal, cartilage and drug delivery. The company also developed a drug development platform for oral versions of a variety of injected peptide drugs. It operates in a single industry segment being pharmaceutical and healthcare industry and one geographical segment in Australia. Calzada is headquartered in Melbourne, Victoria, Australia.
The key business strategies of the company include enhanced focus on developing medical devices using its NovoSorb technology for pharmaceutical and healthcare industry. It also aims to maintain its existing partnerships and to enter new collaborative agreements to fuel its services. This intent can be indicated from the recent collaborations with major US medical device company, for conducting a one year feasibility study on a specific application of PolyNovo’s biodegradable polymer technology. Its key strategies also include the development of NovoSkin BTM to pilot clinical trial and support SNN activities.
Calzada Limited Key Recent Developments
Aug 28, 2013: calzada limited preliminary final report Feb 25, 2013: Calzada Reports H1 Fiscal 2013 Results
This comprehensive SWOT profile of Calzada Limited provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of GlobalData’s -Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Calzada Limited including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).
The profile contains critical company information including*,
– Business description – A detailed description of the company’s operations and business divisions. – Corporate strategy – Analyst’s summarization of the company’s business strategy. – SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. – Company history – Progression of key events associated with the company. – Major products and services – A list of major products, services and brands of the company. – Key competitors – A list of key competitors to the company. – Key employees – A list of the key executives of the company. – Executive biographies – A brief summary of the executives’ employment history. – Key operational heads – A list of personnel heading key departments/functions. – Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. – Key manufacturing facilities – A list of key manufacturing facilities of the company. – Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. – Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. For more information kindly visit : http://www.companyprofilesandconferences.com/researchindex/Pharmaceuticals-Healthcare-c13/Calzada-Limited-CZD-Financial-and-Strategic-SWOT-Analysis-Review1.html